INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Summary

The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (EB).

Timeline

Start

2021-12-28

Primary completion

2023-04-03

Completion

2023-04-19

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “In this study, designed to measure safety and obtain preliminary evidence of efficacy, there is no single primary efficacy endpoint.” inmedpharma.com ↗

Drugs

Indications